LA JOLLA, Calif. -- (BUSINESS WIRE) -- DermTech International, a diagnostics company developing and marketing novel non-invasive gene expression tests to aid in the diagnosis of various skin conditions, today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined.
Maxim Group LLC is acting as lead book-running manager for the offering. Feltl and Company is acting as co-manager for the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.
The offering will be made only by means of a prospectus. Copies of the preliminary prospectus relating to the offering may be obtained, when available, from Maxim Group LLC , Attention: Prospectus Department, 405 Lexington Ave, New York, NY 10174 (800) 724-0761; or from Feltl and Company, Attention: Prospectus Department, 800 LaSalle Avenue, Suite 2100, Minneapolis, MN 55402, (612) 492-8800.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About DermTech International
DermTech International is an emerging diagnostics company developing and marketing novel non-invasive gene expression tests to aid in the diagnosis of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. Our tests analyze skin samples collected non-invasively with an adhesive patch rather than a scalpel. Current dermatologic diagnosis, primarily based on pattern recognition, is subjective and prone to error. In contrast, DermTech’s tests provide objective, biology-based information that is highly accurate.
For additional information visit: www.dermtech.com. DermTech International is based in La Jolla, California.
This press release may contain forward-looking statements, including but not limited to statements regarding DermTech International’s proposed initial public offering, and current and products. These statements relate to future events and are subject to risks, uncertainties and assumptions. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Many factors or events may cause our actual results to differ materially from any forward-looking statement. We do not undertake to update any forward-looking statements.